SRRK Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Scholar Rock Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.78 |
| 52 Week High | US$21.17 |
| 52 Week Low | US$5.93 |
| Beta | 0.80 |
| 1 Month Change | -29.70% |
| 3 Month Change | -42.05% |
| 1 Year Change | 3.66% |
| 3 Year Change | -72.17% |
| 5 Year Change | -41.15% |
| Change since IPO | -43.35% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?
Apr 15
Scholar Rock: Solid Data And Good Prospects
Jan 12Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up
Apr 19Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
Oct 20Jay Backstrom is the new CEO at Scholar Rock
Sep 20Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology
Jul 12Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts
May 21Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher
Mar 08Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be
May 15Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?
May 07If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today
Mar 01We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth
Jan 05
Scholar Rock EPS misses by $0.23, misses on revenue
Nov 09Shareholder Returns
| SRRK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.8% | -2.0% | 1.6% |
| 1Y | 3.7% | 5.4% | 21.5% |
Return vs Industry: SRRK underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: SRRK underperformed the US Market which returned 20.8% over the past year.
Price Volatility
| SRRK volatility | |
|---|---|
| SRRK Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SRRK's share price has been volatile over the past 3 months.
Volatility Over Time: SRRK's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 150 | Jay Backstrom | scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation Fundamentals Summary
| SRRK fundamental statistics | |
|---|---|
| Market cap | US$753.68m |
| Earnings (TTM) | -US$183.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs SRRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRRK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$135.26m |
| Gross Profit | -US$135.26m |
| Other Expenses | US$48.00m |
| Earnings | -US$183.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 27.4% |
How did SRRK perform over the long term?
See historical performance and comparison